Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes (NCT05227677), a randomized na study. The primary outcome is The Achievement Rate of HbA1c (<7%).

2. Clinical Question

The trial addresses a question about using a shorter-term glycemic marker to guide treatment adjustment, rather than simply whether GA was measured. Its stated rationale is that HbA1c may be less sensitive when treatment needs adjustment, while GA reflects average blood glucose over the last 2~3 weeks. Those statements describe the rationale in the registry record, not results from this trial.

The key comparison is therefore between two treatment-adjustment strategies: an approach using a GA threshold and an approach following current guidelines without access to GA values. Since treatment was adjusted according to the assigned strategy, the randomized comparison concerns the overall strategies as implemented, not the isolated effect of a laboratory measurement. The registry record does not report how often treatment was strengthened or what specific medication changes occurred.

Although the record marks the study completed, it does not report the primary outcome counts, achievement rates, or an effect estimate with uncertainty. The central clinical question can be identified, but the comparative answer cannot be determined from the posted results included in the registry record.

3. Trial Design

This was a multicenter, randomized, parallel-group clinical study with no masking. The registry lists an enrollment of 200 and describes a 1:1 assignment to GA-guided treatment adjustment or adjustment according to current guidelines. The study was conducted in 10 hospitals in China and concerned newly diagnosed type 2 diabetes. Its status is completed; the recorded start date is 2022-08-15 and primary completion date is 2024-08-31.

In the GA-guided group, GA was measured at 4-week intervals, and treatment was to be strengthened when the GA value was higher than 16% at 4 weeks. In the comparison group, GA was measured at the same stated intervals, but investigators were not to know the result and were to rely on current guidelines. This design contrasts knowledge of GA and a specified response to a threshold with treatment adjustment that does not use the GA result.

The primary endpoint was achievement of HbA1c <7% at 12 weeks. The record also lists secondary outcomes concerning HbA1c achievement at <6.5% and <6%, changes and rates of change in HbA1c, hypoglycemic events, and changes in HOMA-β and HOMA-IR. The registry lists 16 outcome measures and 34 analyses, but does not describe the full analysis plan for them.

The intervention descriptions identify broad treatment strategies, not detailed medication protocols. The registry record does not report which drugs were used, how investigators applied current guidelines, the frequency or magnitude of treatment changes, or how adherence was assessed. It also does not report masking, which is listed as none. Thus, the reported design supports understanding of the assigned strategies, but not of all their implementation details.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Analysis dataset included two sets. Full analysis set (FAS) was defined as participants who were randomized, met the study inclusion criteria, and had baseline measurements of the primary efficacy endpoint. Per protocol set (PPS) was defined as subjects with good compliance in FAS and no significant protocol deviations that affect the primary efficacy evaluation.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as The Achievement Rate of HbA1c (<7%), measured over 12 weeks.

The primary endpoint is the achievement rate of HbA1c <7% at 12 weeks. It is a binary outcome at the participant level: each participant either meets the stated threshold at the specified assessment or does not. The registry expresses the endpoint as the number of participants and describes the objective as comparing achievement rates between the two groups.

A threshold endpoint translates a continuous laboratory measurement into a clinically interpretable target-attainment outcome. It answers how many participants met the specified HbA1c criterion, rather than how much HbA1c changed on average. These are related but different questions. A group could have a change in average HbA1c without that change necessarily producing the same change in the proportion crossing a threshold.

As a general statistical point, threshold outcomes can be sensitive to where the threshold is placed and to how participants’ measurements are distributed around it. A value just above the cutoff and a value much higher than the cutoff both count as not achieving the target, even though their measured values differ. Conversely, measurements on either side of a cutoff can yield different classifications despite being close numerically.

The registry record does not report the numbers meeting the primary target, the achievement rates, or the between-group estimate. Therefore, the endpoint definition is available, but its observed result and precision are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The methods description needs to be read in two layers: the trial design recorded in the registry and general statistical principles that help explain how such a design is usually interpreted. The record gives the randomized parallel-group structure and endpoint definition, but does not report the detailed statistical plan or primary comparison result. General explanations below should not be taken as confirmation that a particular model or analysis was used in this trial.

What does randomization contribute?

In general, randomization assigns participants to groups using a chance-based process. It is intended to make groups comparable, on average, with respect to both measured and unmeasured characteristics at assignment. That helps support interpretation of a between-group difference as an effect of the assigned strategies, provided that outcome ascertainment and analysis are appropriately handled. Randomization does not guarantee that groups will be identical, and it does not remove the need to report the actual outcome data.

The registry identifies the study as randomized, with a 1:1 allocation, parallel model, and no masking. It does not report the random sequence method, any allocation concealment procedures, or whether the analysis followed assignment regardless of treatment changes. Those details are not reported in the registry record.

What kind of endpoint is being compared?

The primary outcome is binary: achievement or non-achievement of HbA1c <7% at 12 weeks. For a binary endpoint, a basic summary is the number of participants meeting the criterion relative to the number assessed in each group. A comparison can then be expressed using an absolute difference in achievement rates, a relative measure, or another prespecified effect measure. These summaries answer different questions, and the effect measure should be identified explicitly.

The posted record does not provide primary endpoint counts or a comparison measure. It also does not report a confidence interval or p-value. As a general principle, an effect estimate describes the observed contrast, while a confidence interval describes the statistical uncertainty around that estimate under the assumptions of the analysis. A narrow interval indicates greater precision than a wide interval, but neither should be interpreted without considering the design, data quality, and chosen estimand. No such estimate or interval is available for the primary result in the registry record.

What does the absence of masking mean?

The study is listed as having no masking. In general, lack of masking means that relevant people involved in the study may know which strategy was assigned. This can matter differently for different outcomes. A laboratory value may be less dependent on judgment than an outcome requiring subjective assessment, but treatment decisions are part of the intervention in this study and could be affected by awareness of group assignment. The record does not describe procedures to limit such influences or whether laboratory assessors were masked.

Here, the two strategies intentionally differ in whether investigators know GA results. This is part of the intervention contrast, not merely a measurement detail. The comparison is consequently about a GA-informed treatment approach versus guideline-based adjustment without investigator access to GA values, as described in the registry. The record does not provide further information about treatment implementation or adherence.

How should multiple outcomes be considered?

The registry lists 16 outcome measures and 34 analyses. When a study examines multiple outcomes, time points, or comparisons, the chance of at least one apparently notable result can increase if each is interpreted without regard to multiplicity. General methods for addressing this include prespecifying a primary outcome, defining a testing hierarchy, or adjusting inference for multiple comparisons. The registry record does not report whether any such approach was planned or used. The number of listed measures and analyses alone does not establish that a particular correction was applied.

The record marks the primary outcome as having several categories or time points and does not reduce it to one comparison in the associated analysis information. This makes it especially important not to infer a single result from the endpoint label alone. The primary endpoint title names HbA1c <7% at 12 weeks, but the actual outcome counts and analysis are not reported.

What do the sample-size illustrations represent?

General sample-size calculations estimate the amount of information needed to detect a chosen effect under stated assumptions. The registry description says the planning illustrations use the observed effect, a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the effect to detect set as a stated fraction of the observed effect. Such illustrations are not the trial's own design justification and are not observed power. They do not show the probability that the completed study's result is true, nor do they replace the observed effect estimate and its uncertainty.

The registry record does not report a sample-size justification for the original trial design. Because the primary comparison is not reported, no conclusion about the adequacy of the study's information for that comparison can be drawn from the endpoint description alone. Any planning illustration should be interpreted as conditional on its assumptions, not as a substitute for reporting the observed result.

What statistical details are missing?

The record does not report the primary analysis model, the effect measure, the confidence interval method, or the handling of missing endpoint measurements. It also does not report whether covariate adjustment was used, whether any interim analyses occurred, or what statistical plan was specified before analysis. Those details are not reported in the registry record. General methods can explain why they matter, but cannot establish which methods were applied in this study.

For binary outcomes, the analysis should clearly define the population included in the denominator and how participants without an endpoint measurement are handled. The choice can affect the estimate if missingness is related to treatment assignment or outcome status. The registry describes analysis populations but does not report the number assessed for the primary endpoint in either group or the missing-data approach. The posted information therefore supports an explanation of the intended comparison, but not an independent reconstruction of its statistical result.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 16 outcome measures and 34 analyses, including the primary HbA1c target and several secondary outcomes involving HbA1c, hypoglycemic events, HOMA-β, and HOMA-IR. When multiple outcomes or analyses are examined, multiplicity can make isolated results harder to interpret: the more comparisons considered, the more opportunity there is for an apparently notable result to arise by chance. This is a general statistical concern, not evidence that any particular reported result is misleading.

The registry record does not report a multiplicity adjustment, a testing hierarchy, or a complete prespecified analysis plan. It also marks the primary outcome information as involving several categories or time points and does not reduce it to one comparison. No specific inference strategy should therefore be attributed to the investigators based on the available record.

The primary population description identifies a full analysis set as participants who were randomized, met inclusion criteria, and had baseline measurements of the primary efficacy endpoint. It also identifies a per protocol set as subjects with good compliance in the full analysis set and no significant… The description is incomplete at that point; the remaining definition is not reported in the registry record. The registry does not report how many participants were included in either analysis population or which population was used for the primary result.

Missing-data methods are not reported in the registry record. There is no description of how missing 12-week HbA1c measurements were handled, whether any imputation was performed, or whether sensitivity analyses examined alternative assumptions. Without those details and the primary outcome counts, the effect of missing data on the comparison cannot be assessed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 4% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: hypokalemia (1.0%), breast cancer (1.0%).

The registry reports serious adverse events and other adverse events separately. In the GA-guided group, serious adverse events were recorded for 0 participants among 98 at risk, and other adverse events for 18 among 98. In the current-guidelines group, serious adverse events were recorded for 2 participants among 102 at risk, and other adverse events for 9 among 102. The record reports 0 deaths in each group.

The serious adverse-event terms listed are hypokalemia and breast cancer, each shown as 1.0%. The registry information available does not assign these terms to a specific group, so they should not be attributed to one. These figures describe reported events within the recorded categories; they are not the primary efficacy outcome.

As a general statistical point, event counts are descriptive and may be imprecise, particularly when events are uncommon. A comparison of safety between groups would require clear definitions, consistent ascertainment, follow-up information, and an analysis that accounts for uncertainty. The registry record does not provide a comparative safety estimate, confidence interval, or detailed event definitions. The reported counts therefore should not be treated as proof of a difference or of no difference in safety.

The at-risk denominators shown for these safety outcomes are not a substitute for the primary endpoint denominators, which are not reported. Nor do the counts alone describe the timing, duration, severity beyond the serious/non-serious grouping, or relationship of events to treatment.

12. What the Result Does, and Does Not, Mean

The trial's stated purpose was to assess whether knowing GA values and adjusting anti-diabetic treatment according to those values would improve glycemic control in newly diagnosed type 2 diabetes. The registry specifies a randomized comparison between that approach and treatment adjustment according to current guidelines, with achievement of HbA1c <7% at 12 weeks as the primary endpoint.

What the record does not provide is the primary outcome result. Without the number of participants achieving the target in each group, the comparative estimate, and its uncertainty, the result cannot show whether target achievement differed, in which direction it differed, or how precisely any difference was estimated. The study's completed status and its design description do not answer those questions.

The safety counts provide limited descriptive information: they report serious and other adverse events and deaths by group. They do not supply a comprehensive safety comparison or a measure of uncertainty. The listed serious-event terms also cannot be assigned to a group from the information available in the registry record.

As a general interpretation principle, a target-attainment outcome is not the same as a continuous change in HbA1c. The registry lists change in HbA1c among secondary outcomes, but does not report those results. The primary endpoint alone, even if its results were available, would address the proportion meeting a specified threshold at the stated follow-up, not every aspect of glycemic control or treatment experience.

The record also does not establish which specific medicines or treatment changes were made, how well the strategies were followed, or how findings might apply outside the study setting. Those details are not reported in the registry record. The defensible conclusion is therefore limited: the registry describes the question and planned comparison, but the posted information does not report the comparative primary result needed to judge what the trial observed.

13. Why This Trial Matters Statistically

This trial is statistically interesting because it compares treatment strategies that differ in how a biomarker is used to guide decisions. The intervention is not simply measurement of GA: the registry describes a rule for strengthening treatment when GA was higher than 16% at 4 weeks. The comparison group also had GA measured, but investigators were not to know the result and were to rely on current guidelines. The design therefore focuses on the consequences of access to the measurement within a treatment-adjustment strategy.

The primary outcome translates glycemic control into achievement of HbA1c <7% at 12 weeks. This makes the outcome easy to state, while also leaving a statistical distinction between target attainment and change in the continuous measurement. The registry also lists HbA1c change and other secondary outcomes, but their results are not reported in the record available for interpretation.

Randomization and a parallel-group design are useful features for a comparative question, while the absence of masking makes the implementation of treatment strategies important to understand. In this study, awareness of GA is part of the intended contrast; other effects of knowing assignment could also matter in general. The registry does not describe procedures for addressing those possibilities.

The main statistical limitation is not a complicated reported estimate, but the absence of the primary comparative result and its uncertainty. Without those, readers cannot assess effect size, precision, or whether the target-achievement results were compatible with little or substantial differences. The record's multiple listed outcomes and analyses also make the undisclosed analysis strategy relevant to interpretation.

The study illustrates why a complete clinical-trial record needs more than an endpoint definition and completion status. Reporting group-level outcome data, a clear effect measure, uncertainty, analysis populations, and missing-data handling is necessary for readers to evaluate the evidence. Those elements are not reported for the primary comparison in the registry record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most consequential limitation for interpreting this trial record is that the primary outcome result is not reported. The registry identifies the endpoint and its 12-week timeframe but does not provide group achievement counts, rates, a comparative estimate, confidence interval, or p-value. The efficacy comparison therefore cannot be evaluated from the information recorded.

Several statistical details are also absent. The registry record does not report the analysis model, the effect measure, the handling of missing primary endpoint measurements, or whether any covariate adjustment or sensitivity analysis was used. Although full analysis set and per protocol set populations are described, the per protocol definition is incomplete in the available text, and the numbers included in either population are not reported.

The record lists multiple outcome measures and analyses but does not describe a multiplicity strategy or provide the associated comparative results. It also does not report the trial's original sample-size justification. The planning-illustration assumptions described in the record are not a substitute for that justification or for the observed primary result.

Implementation details are limited. The intervention descriptions state the GA measurement interval and the threshold for strengthening treatment, but do not identify specific medications or report actual treatment changes, adherence, or how current guidelines were applied. The study is listed as unmasked, and the record does not describe any additional procedures for limiting potential effects of awareness of assignment.

Finally, the safety information consists of event counts and listed terms without a comparative uncertainty estimate or detailed event definitions. These limitations do not show that the study was conducted improperly; they identify what cannot be assessed from the registry record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes — NCT05227677.
• Registry record last updated 2025-12-04; status last verified 2025-11.
• Results first posted 2025-12-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes a completed, randomized, parallel-group, unmasked study of GA-guided anti-diabetic treatment adjustment versus adjustment according to current guidelines in newly diagnosed type 2 diabetes. The study was planned for 200 participants, with 1:1 allocation, at 10 hospitals in China. The recorded start date is 2022-08-15 and the primary completion date is 2024-08-31.

The primary endpoint was achievement of HbA1c <7% at 12 weeks. The record also lists secondary glycemic, hypoglycemic-event, HOMA-β, and HOMA-IR outcomes. It reports selected adverse-event counts and no deaths in either group.

The registry record does not report the primary outcome comparison, its effect estimate, or its uncertainty. It also does not report key analysis details, including how missing endpoint data were handled. As a result, the record describes the trial question and design but does not provide enough primary efficacy information to interpret the trial's comparative result.